Globe Life's Health Premium Growth Strengthens 2026 Outlook

Globe Life's health premiums rose 16% year over year in Q2 2026, led by a 29% increase at United American and 9% growth at Family Heritage, versus 3% growth in life premiums. Management expects health premiums to grow 14%-16% in 2026 and total premiums to rise 6.5%-7%, aided by approximately $65 million of additional premium from approved Medicare Supplement rate increases. Offsetting the positive growth outlook, GL trades at 2.13x forward price-to-book versus a 1.67x industry average, while 2026 Q4 and 2027 EPS consensus estimates declined 1.3% and 0.5%, respectively, over 60 days.

Analysis

The investable question is not premium growth but whether incremental health premium earns an adequate return after claim trend, reserve development and acquisition costs. Medicare Supplement rate actions can initially lift written premium while creating lapse/anti-selection risk: healthier policyholders may leave after increases, worsening the remaining pool's loss ratio over the next 2-6 quarters. GL's mix shift therefore deserves a lower, not higher, multiple until management demonstrates stable benefit ratios and statutory capital generation through at least two rate cycles.

Relative economics favor UNM over GL. UNM's voluntary-benefits platform is more employer-distributed, which should produce lower policy acquisition friction and better persistency than individually marketed senior-health products; its recent profit growth also indicates that underwriting leverage is already reaching income rather than merely premium. AFL remains a useful defensive alternative, but its U.S. premium trajectory requires evidence of sales recovery before treating it as a direct positive read-through from GL.

Near term, this is unlikely to create a new GL earnings catalyst because estimate revisions are effectively flat and the stock already carries a premium valuation. Over 1-3 months, quarterly disclosure of health loss ratios, Medicare Supplement retention, and expense ratios is the critical test. A sustained deterioration in benefit ratios or a reserve strengthening would expose the market's tendency to capitalize top-line growth too generously; conversely, a clean quarter showing health growth converting into operating-margin expansion would falsify the relative-short case.

Key Decisions for Investors

• Initiate a 3-6 month pair: long UNM / short GL in equal dollar amounts. Target 10-15% relative return if UNM's earnings conversion and lower valuation are rewarded while GL's premium multiple normalizes; exit if GL reports two consecutive quarters of stable/improving health benefit ratios and health segment margins expand.
• Do not add directional GL exposure ahead of the next earnings release. Place an alert on Medicare Supplement persistency, health loss ratio and reserve commentary; buy only if premium growth is accompanied by operating-income growth exceeding premium growth, not simply rate-driven written premium.
• For existing GL longs, trim into strength and retain upside only via defined-risk calls after earnings rather than cash equity. The asymmetric downside is a claims/reserving surprise, while consensus revisions do not currently provide sufficient earnings-momentum support.
• Maintain AFL as a watch item rather than a sympathy long. Reassess on evidence of improving U.S. sales or earned-premium stabilization; absent that, GL's health momentum is more likely competitive share reallocation than a sector-wide demand signal.